



RECEIVED

NOV 05 2003

/1647/

CASE DM-7029 NP

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450..

John A. Lamerdin, Ph.D.

Type or print name

Signature

10/13/03

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1647

BROWN ET AL.

Examiner: Gucker, S.

APPLICATION NO: 09/454,868

FILED: DECEMBER 3, 1999

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY
OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL
DISORDERS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575

Date: 10/13/03

John A. Lamerdin, Ph.D.
Attorney for Applicants
Reg. No. 44,858

RECEIVED

NOV 05 2003

CASE DM-7029 NP

TECH CENTER 1600/2900



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

John A. Lamerdin, Ph.D.
Type or print name

Signature

10/12/03
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1647

BROWN ET AL.

Examiner: Gucker, S.

APPLICATION NO: 09/454,868

FILED: DECEMBER 3, 1999

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY
OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL
DISORDERS

MAIL STOP: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

An English language version of the abstract of Japanese Patent No. 9-191882 is enclosed.


10/21/2003 HGUTERA1 00000007 193880 09454868

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575



John A. Lamerdin, Ph.D.
Attorney for Applicants
Reg. No. 44,858

Date: 10/12/03

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
DM-7029 NP
APPLICATION NO.
09/454,868
APPLICANT
BROWN ET AL.
FILING DATE
DECEMBER 3, 1999

Sheet 1 of 2

RECEIVED
NOV 05 2003
TECH CENTER 1600/2900
Group
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	JP9191882	7/29/97	Japan			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	NCBI Accession No. gi:1841341, Yokyama, et al., March 18, 1999
	AS	Yang, et al. (1997) Proc. Natl. Acad. Sci. 94:4017-4021
	AT	Pongs (1992) Physiological Reviews 72(4):S69-S88

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
DM-7029 NP
APPLICATION NO.
09/454,868
APPLICANT
BROWN ET AL.
FILING DATE
DECEMBER 3, 1999

Sheet 2 of 2

RECEIVED
NOV 05 2003
TECH CENTER 1600/2900
Group
1647



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Jan, et al. (1992) Annual Rev. Physiol. 54:537-555
2AB	Catterall (1995) Annu. Rev. Biochem. 64:493-531
2AC	Yokoyama, et al. (1996) DNA Research 3:311-320
2AD	Editor: Cook (1990) - Potassium Channels, Structure, Classification, Function and Therapeutic Potential; Ellis Horwood Ltd. Publisher
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.